Welcome to our dedicated page for Vsee Health SEC filings (Ticker: VSEEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings and related disclosures for VSee Health, Inc. (Nasdaq: VSEE, VSEEW), a telehealth technology and services company in the health services sector. The company describes itself as delivering high-acuity virtual care solutions through a scalable, API-driven platform that integrates secure video, device data, and EHR connectivity.
Although specific forms are not listed here, VSee Health has referenced SEC reporting in its public communications. In connection with regaining compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Equity Rule, the company stated that it filed a pro forma balance sheet on Form 8-K/A reflecting capital transactions such as conversion of convertible notes into common stock, cash exercise and exchange of certain public warrants, and a private placement of common stock or pre-funded warrants with accompanying warrants.
On Stock Titan, users can review VSee Health’s historical and future SEC submissions as they become available, including current reports on Form 8-K that describe material events affecting its capital structure, listing status, or business. For a telehealth and digital health company, such filings can provide additional context on areas like financing arrangements, equity transactions, and other corporate actions that support its telehealth, remote patient monitoring, and digital health services.
AI-powered tools on this page summarize lengthy filings, highlight key sections, and make it easier to understand how reported events relate to VSee Health’s telehealth platform and Nasdaq Capital Market listing. Users can use these summaries to quickly identify important disclosures without reading every page of each filing.
VSee Health, Inc. reported that stockholders approved a key share issuance related to a private placement at a special meeting held on March 2, 2026. The meeting had a quorum, with 21,824,877 votes represented, or 50.46% of shares entitled to vote.
Stockholders approved issuing common shares to certain holders of warrants to purchase up to 19,672,130 shares of common stock, as required under Nasdaq Listing Rule 5635(d). The proposal passed with 14,109,726 votes for, 7,698,963 against, and 16,188 abstentions. An adjournment proposal was also approved but withdrawn because the main private placement proposal received sufficient support.
VSee Health, Inc. reported that stockholders approved a key share issuance related to a private placement at a special meeting held on March 2, 2026. The meeting had a quorum, with 21,824,877 votes represented, or 50.46% of shares entitled to vote.
Stockholders approved issuing common shares to certain holders of warrants to purchase up to 19,672,130 shares of common stock, as required under Nasdaq Listing Rule 5635(d). The proposal passed with 14,109,726 votes for, 7,698,963 against, and 16,188 abstentions. An adjournment proposal was also approved but withdrawn because the main private placement proposal received sufficient support.
VSEE HEALTH, INC. director-related entity FWE Capital LLC converted convertible promissory notes into shares of common stock. On February 23, 2026, the LLC acquired 759,916 shares of common stock at $0.3200 per share and 105,251 shares at $0.6500 per share through derivative conversions.
After these conversions, FWE Capital LLC held 1,147,564 shares and 387,648 shares of VSEE common stock in two separate indirect ownership positions for reporting person David L. Wickersham. The filing notes that the underlying notes included both principal and interest.
VSEE HEALTH, INC. director-related entity FWE Capital LLC converted convertible promissory notes into shares of common stock. On February 23, 2026, the LLC acquired 759,916 shares of common stock at $0.3200 per share and 105,251 shares at $0.6500 per share through derivative conversions.
After these conversions, FWE Capital LLC held 1,147,564 shares and 387,648 shares of VSEE common stock in two separate indirect ownership positions for reporting person David L. Wickersham. The filing notes that the underlying notes included both principal and interest.
VSee Health, Inc. Schedule 13G/A discloses that the reporting persons beneficially own 833,331 shares, representing 2.0% of the class. The reported position consists of Public Warrants to purchase 702,896 shares plus 130,435 shares issuable under a Warrant Exchange Agreement. The percentage calculation references 40,230,845 shares outstanding as of February 2, 2026, plus the 833,331 issuable shares.
VSee Health, Inc. Schedule 13G/A discloses that the reporting persons beneficially own 833,331 shares, representing 2.0% of the class. The reported position consists of Public Warrants to purchase 702,896 shares plus 130,435 shares issuable under a Warrant Exchange Agreement. The percentage calculation references 40,230,845 shares outstanding as of February 2, 2026, plus the 833,331 issuable shares.
VSee Health, Inc. entered a managed services agreement with GoMyRx, Inc. under which VSee will provide platform administration, customer support, vendor coordination, and reporting services. VSee will bill GoMyRx monthly for actual expenses plus a 10% markup, and the agreement runs through December 26, 2027, with optional month-to-month extensions for six months.
Separately, VSee agreed to purchase $2.0 million of GoMyRx common stock from Go Biz Holdings, LLC in a private transaction, representing a 10% ownership stake in GoMyRx. The shares are restricted securities issued under Section 4(a)(2) and Rule 506 of Regulation D.
VSee Health, Inc. entered a managed services agreement with GoMyRx, Inc. under which VSee will provide platform administration, customer support, vendor coordination, and reporting services. VSee will bill GoMyRx monthly for actual expenses plus a 10% markup, and the agreement runs through December 26, 2027, with optional month-to-month extensions for six months.
Separately, VSee agreed to purchase $2.0 million of GoMyRx common stock from Go Biz Holdings, LLC in a private transaction, representing a 10% ownership stake in GoMyRx. The shares are restricted securities issued under Section 4(a)(2) and Rule 506 of Regulation D.
VSee Health, Inc. director David L. Wickersham reported an "other" insider transaction involving 100,000 shares of common stock at a stated value of $2.00 per share. According to the filing, he received these shares from Co-Chief Executive Officer Imoigele Aisiku as full repayment of a $200,000 personal loan. Following this transfer, Wickersham directly holds 214,000 shares of VSee Health common stock.
VSee Health, Inc. director David L. Wickersham reported an "other" insider transaction involving 100,000 shares of common stock at a stated value of $2.00 per share. According to the filing, he received these shares from Co-Chief Executive Officer Imoigele Aisiku as full repayment of a $200,000 personal loan. Following this transfer, Wickersham directly holds 214,000 shares of VSee Health common stock.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported two stock transfers used to repay personal loans. On August 15, he transferred 25,000 common shares at $2.00 per share in full satisfaction of a $50,000 personal loan. On August 14, he transferred 100,000 common shares at $2.00 per share to board member David Wickersham to fully repay a separate $200,000 personal loan made to him by Mr. Wickersham. Following these transactions, his reported direct holdings remained above 3.2 million common shares.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported two stock transfers used to repay personal loans. On August 15, he transferred 25,000 common shares at $2.00 per share in full satisfaction of a $50,000 personal loan. On August 14, he transferred 100,000 common shares at $2.00 per share to board member David Wickersham to fully repay a separate $200,000 personal loan made to him by Mr. Wickersham. Following these transactions, his reported direct holdings remained above 3.2 million common shares.
VSee Health, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,889,308 shares of Common Stock, representing 9.99% of the class as of 12/31/2025.
The filing states Armistice Capital is investment manager of the Master Fund, which directly holds the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own those shares. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement with Armistice Capital. Signatures are dated 02/17/2026.
VSee Health, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,889,308 shares of Common Stock, representing 9.99% of the class as of 12/31/2025.
The filing states Armistice Capital is investment manager of the Master Fund, which directly holds the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own those shares. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement with Armistice Capital. Signatures are dated 02/17/2026.
VSee Health, Inc. has called a virtual special meeting on March 2, 2026 to ask stockholders to approve a prior private placement under Nasdaq Listing Rule 5635(d). The company sold 9,836,065 shares of common stock (or pre-funded warrants) plus warrants for up to 19,672,130 shares in a November 2025 private offering, raising approximately $6 million at $0.61 per share.
Stockholders are being asked to approve the potential issuance of the warrant shares, which would exceed 20% of currently outstanding common stock, and to authorize possible adjournment of the meeting if more time is needed to gather votes. Common and Series A Preferred holders of record on February 2, 2026 are entitled to vote.
VSee Health, Inc. has called a virtual special meeting on March 2, 2026 to ask stockholders to approve a prior private placement under Nasdaq Listing Rule 5635(d). The company sold 9,836,065 shares of common stock (or pre-funded warrants) plus warrants for up to 19,672,130 shares in a November 2025 private offering, raising approximately $6 million at $0.61 per share.
Stockholders are being asked to approve the potential issuance of the warrant shares, which would exceed 20% of currently outstanding common stock, and to authorize possible adjournment of the meeting if more time is needed to gather votes. Common and Series A Preferred holders of record on February 2, 2026 are entitled to vote.
VSEE Health, Inc. received an amended Schedule 13G/A from a group led by Dominion Capital and Ascent Partners reporting reduced beneficial ownership of its common stock. The group now beneficially owns 1,014,654 shares, or about 2.97% of the company, based on 33,193,140 shares outstanding as of December 26, 2025.
The position includes 100,000 shares issued as closing shares under a March 20, 2025 promissory note and common stock purchase warrants exercisable for additional shares. The filers state this is an exit filing because they no longer own more than 5% and certify the holdings are not for control purposes.
VSEE Health, Inc. received an amended Schedule 13G/A from a group led by Dominion Capital and Ascent Partners reporting reduced beneficial ownership of its common stock. The group now beneficially owns 1,014,654 shares, or about 2.97% of the company, based on 33,193,140 shares outstanding as of December 26, 2025.
The position includes 100,000 shares issued as closing shares under a March 20, 2025 promissory note and common stock purchase warrants exercisable for additional shares. The filers state this is an exit filing because they no longer own more than 5% and certify the holdings are not for control purposes.
VSee Health, Inc. (VSEE) amended its 2024 annual report to correct multiple accounting errors, restate interim periods and disclose material financing and acquisition activity. The company identified repeated failures to accrue sales and use taxes, resulting in cumulative accrual increases peaking at $940,130 as of September 30, 2024, and multiple revenue cutoff corrections that moved revenue to deferred revenue and opening retained earnings. The firm recorded substantial purchase accounting adjustments tied to the June 24, 2024 business combination and iDoc acquisition, including adjustments to goodwill and acquired receivables that led to a significant goodwill impairment charge of $56,675,210 and a net loss of $58,134,446 for the year. Financing activity includes an Exchange Note of $2,523,744, a $3,000,000 Quantum Convertible Note, and an Equity Line (ELOC) commitment up to $50,000,000 (floor price later amended). The filing also discloses defaults, numerous convertible and original-issue-discount notes, material fair-value remeasurements, and explicit risks including uncertainty about continuing as a going concern.